TURNING POINT THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt SecuritiesIndenture • May 15th, 2020 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 15th, 2020 Company Industry JurisdictionINDENTURE, dated as of [●], 20 , among Turning Point Therapeutics, Inc., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):
TURNING POINT THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OFWarrant Agreement • May 15th, 2020 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 15th, 2020 Company Industry JurisdictionTHIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Turning Point Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
TURNING POINT THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFWarrant Agreement • May 15th, 2020 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 15th, 2020 Company Industry JurisdictionTHIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Turning Point Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).